Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP4945)
Name
Hypericin
Synonyms
hypericin; 548-04-9; Hypericum red; hypericine; Cyclosan; hipericina; Hyperizin; Mycoporphyrin; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione; Cyclo-Werol; Hypericum Extract; VIMRxyn; UNII-7V2F1075HD; MFCD00016683; NSC407313; Hypericin & Visible light; 7V2F1075HD; NSC622946; Cyclo werrol; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro(1,10,9,8-opqra)perylene-7,14-dione; hexahydroxy(dimethyl)[?]dione; 1:6:8:10:11:13-hexahydroxy-3:4-dimethyl-meso-naphthodianthrene-7:14-dione; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-; Phenanthro[1,10,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer; C30H16O8; EINECS 208-941-0; NSC 407313; NSC 622946; CCRIS 8166; (component of) Hypericum spp (st. John's wort); BiomolKI_000032; 4,5,7,4',5',7'-Hexahydroxy-2,2'-dimethyl-mesonapthtodianthron; BiomolKI2_000040; SCHEMBL3182; BIDD:PXR0084; BMK1-D8; SCHEMBL10262695; DTXSID40203270; Hypericin - CAS 548-04-9; Hypericin from Hypericum perforatum; HY-N0453; ZINC3780340; BDBM50060874; CCG-36081; HSCI1_000202; LMPK13040001; AKOS015895658; AC-6048; CS-5687; EBD2048972; MCULE-7319800130; NSC-622946; NCGC00162454-01; NCGC00163378-01; NCGC00163378-02; AS-74733; NCI60_003879; NCI60_006799; NCGC00163378-03!; FT-0627169; N2739; C07606; 33919-EP2275420A1; 33919-EP2295055A2; 33919-EP2295416A2; 33919-EP2298748A2; 33919-EP2298764A1; 33919-EP2298765A1; 33919-EP2305642A2; 33919-EP2311453A1; 548H049; SR-05000002344; Hypericin from Hypericum perforatum, ~95% (HPLC); Hypericin, primary pharmaceutical reference standard; Q-100618; SR-05000002344-2; BRD-K29673530-001-03-9; 4,4',5,5',7,7'-Hexahydroxy-2,2'-dimethylnaphthodianthrone; 3,4,6,7,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,8-dione; 3,4,7,8,13,14-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-1,6-dione; 1,3,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione, 9CI; 1,4,6,8,13-Hexahydroxy-10,11-dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-dione P-conformer; 5,7,11,18,22,24-HEXAHYDROXY-13,16-DIMETHYLOCTACYCLO[13.11.1.1(2),(1)?.0(3),?.0?,(2)?.0(1)?,(2)?.0(2)(1),(2)?.0(1)?,(2)?]OCTACOSA-1,3,5,7,10,12,14(28),15(27),16,18,21,23,25-TRIDECAENE-9,20-DIONE; Phenanthro[1,9,8-opqra]perylene-7,14-dione,1,3,4,6,8,13-hexahydroxy-10,11-dimethyl-, stereoisomer
    Click to Show/Hide
Species Origin Hypericum perforatum ...     Click to Show/Hide
Hypericum perforatum
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Malpighiales
Family: Hypericaceae
Genus: Hypericum
Species: Hypericum perforatum
Disease Human immunodeficiency virus disease [ICD-11: 1C62] Phase 1 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C30H16O8
PubChem CID
3663
Canonical SMILES
CC1=CC(=O)C2=C(C3=C(C=C(C4=C3C5=C2C1=C6C(=CC(=O)C7=C(C8=C(C=C(C4=C8C5=C67)O)O)O)C)O)O)O
InChI
1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,33-38H,1-2H3
InChIKey
YDOIFHVUBCIUHF-UHFFFAOYSA-N
CAS Number
CAS 548-04-9
Herb ID
HBIN029828
SymMap ID
SMIT04377
TCMSP ID
MOL002067
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          N-acetylcysteine      Liver disease     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation
Increase Mature biofilm disruption
                    In-vitro Model Staphylococcus aureus Microorganism model Staphylococcus aureus
                    Experimental
                    Result(s)
HYP-PDI in combination with AC had significant ability to eradicate the pre-formed mature biofilms of S. aureus strains.
Target and Pathway
Target(s) COPII-associated small GTPase (SAR1A)  Molecule Info  [3]
References
Reference 1 ClinicalTrials.gov (NCT00000792) A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects
Reference 2 Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms. Photodiagnosis Photodyn Ther. 2015 Jun;12(2):186-92.
Reference 3 Hypericin enhances Beta-lactam antibiotics activity by inhibiting sarA expression in methicillin-resistant Staphylococcus aureus. Acta Pharm Sin B. 2019 Nov;9(6):1174-1182.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China